4/17
09:57 pm
dftx
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? [Yahoo! Finance]
Neutral
Report
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? [Yahoo! Finance]
4/17
02:01 pm
dftx
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones [Seeking Alpha]
Low
Report
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones [Seeking Alpha]
4/17
03:37 am
dftx
Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data [Yahoo! Finance]
Low
Report
Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data [Yahoo! Finance]
4/16
07:03 pm
dftx
Definium Therapeutics (DFTX) was given a new $30.00 price target by Stifel Nicolaus.
Low
Report
Definium Therapeutics (DFTX) was given a new $30.00 price target by Stifel Nicolaus.
4/16
08:07 am
dftx
Definium Therapeutics (DFTX) was given a new $38.00 price target by Canaccord Genuity Group Inc..
Low
Report
Definium Therapeutics (DFTX) was given a new $38.00 price target by Canaccord Genuity Group Inc..
4/10
08:43 am
dftx
Definium Therapeutics (DFTX) is now covered by Piper Sandler. They set an "overweight" rating and a $49.00 price target on the stock.
Low
Report
Definium Therapeutics (DFTX) is now covered by Piper Sandler. They set an "overweight" rating and a $49.00 price target on the stock.
4/9
07:00 am
dftx
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Low
Report
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
4/3
08:40 pm
dftx
Can Definium Therapeutics (DFTX) Turn GAD Prevalence And DT120 Breakthrough Status Into Durable Advantage? [Yahoo! Finance]
Low
Report
Can Definium Therapeutics (DFTX) Turn GAD Prevalence And DT120 Breakthrough Status Into Durable Advantage? [Yahoo! Finance]
3/31
07:00 am
dftx
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
Medium
Report
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
3/30
04:01 pm
dftx
Definium Therapeutics Announces New Employee Inducement Grants
Medium
Report
Definium Therapeutics Announces New Employee Inducement Grants
3/26
07:00 am
dftx
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
Low
Report
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
3/25
05:37 am
dftx
A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum [Yahoo! Finance]
Medium
Report
A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum [Yahoo! Finance]
3/25
01:44 am
dftx
Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 [Yahoo! Finance]
Medium
Report
Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 [Yahoo! Finance]
3/18
11:42 am
dftx
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names [Yahoo! Finance]
Low
Report
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names [Yahoo! Finance]
3/15
06:09 am
dftx
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference [Yahoo! Finance]
Low
Report
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference [Yahoo! Finance]
3/9
04:01 pm
dftx
Definium Therapeutics Announces New Employee Inducement Grants
Medium
Report
Definium Therapeutics Announces New Employee Inducement Grants
3/2
09:04 am
dftx
Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.
Low
Report
Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.
2/28
03:23 pm
dftx
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]
Low
Report
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]
2/26
11:40 pm
dftx
Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
04:14 pm
dftx
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
2/26
04:01 pm
dftx
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
Low
Report
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
2/25
06:24 am
dftx
Definium Therapeutics (DFTX) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Definium Therapeutics (DFTX) was upgraded by Wolfe Research to "strong-buy".
2/24
07:21 am
dftx
Definium Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Definium Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]
2/24
07:01 am
dftx
Definium Therapeutics to Participate at Upcoming Investor Conferences
Low
Report
Definium Therapeutics to Participate at Upcoming Investor Conferences
2/23
06:01 pm
dftx
Definium Therapeutics (NASDAQ:DFTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Definium Therapeutics (NASDAQ:DFTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.